Delivery Order SPE2DB24D2100-SPE2DB25FBCNB

Award Date 3/3/25
Potential Completion Date 3/4/25
Potential Value $4.5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, worth $10,941.27, is for the delivery of IMOVAX Rabies Vaccine Vials under a Firm Fixed Price Delivery Order contract. The contract has an ultimate completion date of January 6, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,677.75, is for the delivery of IMOVAX Rabies Vaccine Vials. It is a firm fixed-price delivery order contract with a completion date of February 24, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of IMOVAX Rabies Vaccine vials, with a ceiling value of $1,313.57 and a performance period through July 2024. This appears to be a delivery order under a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA, valued at $999,999,999 and running through November 2026. The IDC...
The U.S. government agency, the Defense Logistics Agency (DLA) Troop Support Medical, awarded a delivery order contract to Amerisourcebergen Drug Corp's Corporate Office Division, a major supplier of pharmaceutical products and medical supplies. The contract, valued at $3,669.79, is for the provision of IMOVAX Rabies Vaccine vials. This award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, valued at up to $999,999,999.00 through December 31, 2025....
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of IMOVAX Rabies Vaccine Vials, with a ceiling value of $1,514.58 and a completion date of July 29, 2024. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical and medical supply distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the delivery of IMOVAX Rabies Vaccine vials, valued at $4,317.40, with a period of performance through October 9, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999 and...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,336.50 firm fixed-price delivery order is for the procurement of IMOVAX Rabies Vaccine Vials. The contract has an ultimate completion date of March 4, 2025 and was awarded on March 3, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,113.75, is for the delivery of IMOVAX Rabies Vaccine Vials. It is a firm fixed-price delivery order contract with an ultimate completion date of January 7, 2025. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,113.75, is for the delivery of IMOVAX Rabies Vaccine Vials to support military healthcare programs. The contract is a Firm Fixed Price Delivery Order with a completion date of February 12, 2025. The contract is not set aside and was awarded through open competition. Amerisourcebergen Drug Corp...
This federal contract award is for the delivery of IMOVAX Rabies vaccine vials to the Defense Logistics Agency (DLA). The contract, valued at $1,339.98, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a firm fixed-price pricing type and an ultimate completion date of December 10, 2024. The contract is a delivery order and is not designated as a set-aside. AmerisourceBergen holds a larger Indefinite Delivery...
  • SPE2DB24D2100
    Indefinite Delivery Contract
  • SPE2DB24D2100-SPE2DB25FBCNB
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of IMOVAX Rabies Vaccine Vials. The fixed-price delivery order, valued at $4,455.00, has a completion date of March 4, 2025.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award reviewed was not designated with any set-aside requirements, indicating open competition.

Generated 6/2/25, 9:57 AM